News and Events
SomaLogic announced today that it has launched three additional SomaSignal™ tests to further empower individuals to manage their state of health more effectively. These new blood-based tests measure glucose tolerance, visceral fat and resting energy rate.
Sign up to receive our news releases
Proteins in our blood could in future help provide a comprehensive way to assess our health status and predict the likelihood that we will develop a range of diseases, according to research published today in Nature Medicine. The study, by an international team of researchers led by scientists at the University of California, San Francisco, Cambridge University in the UK and SomaLogic, shows that large-scale measurement of proteins in a single blood test can provide important information about a wide range of health factors and can help to predict a range of disease risks.
SomaLogic, a privately held precision health information company, announced today that it has appointed Anne Margulies, Harvard University Vice President and Chief Information Officer, Franck J. Moison, former Vice Chairman of Colgate-Palmolive, and private investor Richard “Rick” Post to its board of directors. All three bring distinct expertise and experience to help guide the next phase of SomaLogic’s growth.
SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts. The agreement includes plans to analyze at least 250,000 clinical samples from across the Novartis drug development portfolio.
SomaLogic announced today that Patrick Terry has joined the company as its first Chief Commercial Officer (CCO). A serial entrepreneur, biomedical science enthusiast and patient advocate, Terry is uniquely qualified to lead the commercialization of SomaLogic’s growing portfolio of protein-based precision health information products.
SomaLogic today launched its first seven SomaSignal™ tests, which are delivered simultaneously to provide actionable health information across a diverse set of human diseases and conditions. Each SomaSignal™ test is built on SomaLogic’s proprietary SomaScan® Platform, which measures thousands of human proteins in a single blood sample. The company expects that eventually there will be hundreds of different SomaSignal™ tests on the SomaScan® Platform.
SomaLogic announced today that its United States clinical laboratory (CLIA laboratory) has been re-accredited by the College of American Pathologists (CAP). The successful renewal of CAP accreditation is based on the results of a recent on-site inspection designed to ensure the highest laboratory standards.
Agilent Technologies, Inc. (NYSE: A) and SomaLogic, Inc. (a privately held biotechnology company) today announced a multi-year supply agreement whereby Agilent will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step within SomaLogic’s novel SomaScan assay, a protein measurement platform with applications across basic and clinical research, diagnostics, and pharmaceutical discovery and development.
SomaLogic CEO Roy Smythe, M.D. announced today that Melody Harris has been appointed President of SomaLogic. Ms. Harris joined SomaLogic in April 2018 as Chief Legal Officer from Qualcomm Life, a digital health subsidiary of Qualcomm, where she led global and strategic deals with companies such as Novartis, Philips, Abbvie, United Healthcare, Walgreens, and WebMD as Vice President & Chief Counsel.
SomaLogic, Inc. announced today that it has entered into a collaborative agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement terms, SomaLogic will analyze ~5000 proteins in each of at least 15,000 clinical samples from Janssen to identify and validate protein biomarkers for use by Janssen and SomaLogic in predicting, diagnosing, monitoring, and treating disease.